What Hepatitis B Carriers Should Know: What to Monitor, When to Start Antivirals, and Why Immunosuppression (Including Dialysis and Transplant) Can Reactivate the Virus

Why hepatitis B matters so much in Asia

WHO estimates that in 2022 about 254 million people were chronically infected with hepatitis B virus (HBV) and about 1.1 million died, mostly from cirrhosis and liver cancer [1]. In Taiwan, adults born before universal infant vaccination in 1986 have a carriage rate of about 10–13%; in Japan it is about 1%. Asian infections are mostly acquired at birth or in early childhood from the mother, which is why chronicity is so common [1].

Having no symptoms does not make hepatitis B safe — most carriers feel well until cirrhosis or cancer is found.

Reading the lab report

What carriers should monitor, and how often

For untreated carriers EASL 2025 and AASLD advise [2][3]:

• Every 6–12 months: ALT and HBV DNA.
• Every 6 months: liver ultrasound (± AFP) for cancer surveillance — in cirrhosis, men >40, women >50, or a family history of liver cancer; Taiwan's national insurance funds regular ultrasound for carriers.
• Every 1–3 years: fibrosis assessment (FIB-4, FibroScan).

Who needs antivirals? The criteria are widening

Treatment used to be reserved for high ALT plus high viral load; WHO 2024 broadened this substantially — any one of the following qualifies [1]:

1. Evidence of cirrhosis (any viral load), or APRI >0.5 / FibroScan ≥7 kPa.
2. HBV DNA >2,000 IU/mL with ALT above the upper limit of normal.
3. Co-morbidities or special situations: HIV, HCV or HDV co-infection, diabetes, fatty liver, family history of liver cancer, extrahepatic manifestations (e.g. glomerulonephritis), or receiving immunosuppression.
4. HBV DNA >2,000 IU/mL even with normal ALT if over 30 (conditional WHO recommendation).

EASL 2025 goes further: all adults with HBV DNA >2,000 IU/mL may be considered for treatment regardless of ALT, to reduce liver cancer [2].

Which drugs

First-line are high-barrier nucleos(t)ide analogues [1][2][3]:

These drugs suppress rather than cure the virus, so most people take them long term or lifelong; stopping on your own can trigger a severe flare, and any discontinuation must be supervised with close monitoring [2][3].

What kidney patients most need to know: immunosuppression and HBV reactivation

When the immune system is suppressed, latent virus can replicate massively — HBV reactivation — and in severe cases cause acute liver failure. Even after HBsAg has cleared and only anti-HBc remains positive, viral DNA may persist in hepatocytes [2][3][4].

High-risk settings:

• B-cell-depleting agents (rituximab — used in some glomerulonephritides and transplant rejection): high reactivation rates; prophylaxis is needed even when HBsAg-negative/anti-HBc-positive.
• Immunosuppression after kidney transplantation.
• High-dose steroids (≥20 mg prednisolone for >4 weeks).
• Chemotherapy and anti-TNF or other biologics.

Recommended approach [2][3][4]:

1. Test HBsAg and anti-HBc before any immunosuppressive therapy (KDIGO and liver-society consensus).
2. HBsAg-positive → start prophylactic antiviral (entecavir or TAF) before immunosuppression, continuing for at least 6–12 months after it ends (18 months for rituximab).
3. HBsAg-negative/anti-HBc-positive → prophylaxis for high-risk therapy (rituximab, transplant); monitor HBV DNA every 1–3 months for moderate/low-risk therapy.

Dialysis patients: dialysis units are a classic setting for HBV transmission; KDIGO recommends regular testing and vaccination, with dedicated machines or isolation areas for HBsAg-positive patients [5]. Vaccine response is poorer in dialysis, often needing double doses (40 µg) or boosters; anti-HBs <10 mIU/mL should prompt a booster [5].

Vaccination remains the most effective prevention

• anti-HBs ≥10 mIU/mL after a complete three-dose series indicates protection; routine boosters are not needed in healthy people.
• CKD, dialysis or pre-transplant: vaccinate as early as possible while eGFR is still higher (better response) and check anti-HBs [5].
• Household members and sexual partners who are uninfected should be vaccinated.

When to seek care

Urgently: jaundice, dark urine, extreme fatigue with nausea, confusion, vomiting blood or black stools — especially if you are on or just finished immunosuppression, or stopped your antiviral.

Routine appointment: a carrier with no follow-up for over a year; about to start steroids, biologics, chemotherapy or transplant work-up; a family member newly diagnosed.

Questions to ask your doctor

1. What are my HBV DNA and ALT? Under the new guidelines, do I qualify for treatment?
2. With my kidney function, is entecavir, TDF or TAF most suitable, and does the dose need adjusting?
3. Do I need a liver ultrasound every 6 months?
4. Does the drug I am starting (steroids, rituximab, anti-rejection therapy) require HBV prophylaxis first?
5. Is my anti-HBs level adequate, or do I need a booster?

References

1. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. March 2024. https://www.who.int/publications/i/item/9789240090903
2. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025. https://doi.org/10.1016/j.jhep.2025.03.018
3. Terrault NA, et al. AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. https://doi.org/10.1002/hep.29800
4. Reddy KR, et al. AGA Institute guideline on HBV reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–219. https://doi.org/10.1053/j.gastro.2014.10.039
5. KDIGO 2018 Clinical Practice Guideline for Hepatitis C in CKD (incl. dialysis infection-control chapter). Kidney Int Suppl. 2018;8(3):91–165. https://doi.org/10.1016/j.kisu.2018.06.001 ; CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1–43. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5005a1.htm

This article compiles publicly available medical information for educational purposes only. It is not medical advice and has not been reviewed by a practising physician. For any health or medication question, consult a qualified professional. For chest pain, sudden breathlessness, one-sided weakness or slurred speech, call your local emergency number or go to the emergency department immediately.